DR. O HOWARD FRAZIER, M.D.

Plain English
This study looked at whether gastrointestinal bleeding raises the risk of blood clots and strokes in patients who have continuous-flow left ventricular assist devices (CF-LVADs). They found that among 1,075 patients, 32.2% experienced gastrointestinal bleeding, and of those, 26.3% had blood clot-related issues later on. The risk of these complications increased by 52% after bleeding, especially in patients over 50 years old and Black patients, who were at twice the risk compared to other groups. Who this helps: This research benefits doctors and healthcare providers managing CF-LVAD patients, especially in monitoring and preventing complications.

Plain English
This study looked at patients with advanced heart failure who received a left ventricular assist device and wanted to see if their prior strokes were linked to problems in their cells' energy-making systems, specifically in mitochondria. They found that patients with a history of stroke had lower levels of certain proteins critical for energy production both before and after the device implantation. These findings are important because reduced energy production could indicate a higher risk of new strokes after surgery, and monitoring these specific proteins could help predict stroke risk in these patients. Who this helps: This helps patients with advanced heart failure, especially those with a history of stroke, and their doctors in managing their risk for stroke after surgery.

Plain English
This paper reviews how heart transplant surgery has changed since the first successful operation in 1967. It highlights improvements in techniques that make the surgery safer and more effective, resulting in better outcomes for patients. These advancements mean more people are surviving and living longer after receiving a heart transplant. Who this helps: Heart transplant patients and the doctors who care for them.

Plain English
This study looked at how long patients survive after receiving heart transplants from two types of donors: those who died from circulatory failure (DCD) and those who died from brain failure (DBD). Out of over 18,000 heart transplants examined, the results showed that in the first year, survival rates were about the same (91.6% for DCD and 91.5% for DBD), but by the second and third years, DCD recipients had lower survival rates at 84.7% and 80.3% compared to 89.4% and 85.6% for DBD recipients. This matters because it highlights that heart transplants from circulatory death donors may lead to worse outcomes over time, indicating a need for more research on the reasons behind these differences. Who this helps: This helps patients needing heart transplants and their doctors in making informed decisions about donor options.

Plain English
This study looked at gastrointestinal (GI) bleeding in patients using continuous-flow left ventricular assist devices (CF-LVADs) between 2008 and 2023. Out of 1,030 patients, 37.5% experienced GI bleeding, with incidents occurring on average 5 months after receiving the device. Older patients (over 50) were three times more likely to bleed, but using a specific type of LVAD design reduced the bleeding risk significantly, by four times compared to another design. Who this helps: This information helps doctors understand and manage the risk of GI bleeding in patients with CF-LVADs.

Plain English
This study focused on improving a device called a left ventricular assist device (LVAD), which helps patients with heart problems while they wait for a transplant. Researchers developed a new kind of motor, called a MagLev motor, that allows better performance of the LVAD by reducing blood-related complications. They found that this motor has strong stability and minimizes contact between moving parts, which helps keep blood flow safer. Who this helps: This benefits patients with severe heart disease who are awaiting transplants.

Plain English
This study looked at infections related to the driveline of Left Ventricular Assist Devices (LVADs) in over 1,000 patients treated between 2008 and 2023. It found that about 40% of patients developed driveline infections within five years, with those who had severe diabetes at a 52% higher risk. Interestingly, older patients (40 and above) had a much lower infection risk, while certain types of LVADs also showed varying risks for infections. Who this helps: This information helps patients with LVADs and their doctors manage infection risks more effectively.

Plain English
This study looked at patients with severe heart failure who had high pressure in their lung blood vessels (a condition called elevated pulmonary vascular resistance, or PVR) and were getting a special device to help their heart (called an LVAD). They found that patients with moderate to severe leakage of blood through the heart's mitral valve (mitral regurgitation, or MR) had better survival rates and higher chances of getting a heart transplant compared to those with mild or no MR—specifically, they had a 36% lower chance of dying and were nearly three times more likely to receive a transplant. These results are important because they suggest that the severity of MR can help doctors choose the best treatment options for patients in severe heart failure. Who this helps: This benefits patients with end-stage heart failure and healthcare providers involved in their treatment.

Plain English
This study focused on creating a computer model to test new heart pumps (left ventricular assist devices or LVADs) for children weighing between 5 and 20 kg who have heart failure. The researchers found that their model closely matched real-life experiments, with differences in results ranging from 0 to 11%, and under challenging conditions, it only varied by 16%. This model is important because it can help design better heart pumps that adapt to the growing needs of pediatric patients. Who this helps: This benefits doctors and children with heart failure who need specialized heart pumps.

Plain English
This study developed a test system that simulates how a real heart works, using a machine to mimic heart function. The researchers created a four-chamber model that can accurately replicate healthy heart behavior and certain heart failure conditions, effectively controlling blood flow and pressure. This is important because it helps in testing heart assist devices more effectively before they are used in patients, ensuring better safety and performance. Who this helps: This benefits patients needing heart assistance devices and the doctors who treat them.

Plain English
This study looked at the effects of low blood pressure (vasoplegia) after patients received a continuous-flow left ventricular assist device (CF-LVAD) to support their heart. Out of 600 patients, 182 (30.3%) experienced vasoplegia, with 78 (13.0%) suffering from prolonged vasoplegia lasting 12 to 24 hours. Those with prolonged vasoplegia had a higher risk of dying within 30 days (16.7%) compared to those with shorter vasoplegia (5.8%), indicating that managing blood pressure issues after surgery is important for better patient survival. Who this helps: This benefits patients who undergo heart surgery and their doctors managing their postoperative care.

Plain English
This study looked at the Jarvik 2000 heart pump, used to help people with severe heart failure while they wait for a heart transplant. Out of 150 patients, 67.3% were successfully either transplanted or listed for a transplant within 180 days, which was better than the expected 65%. The newer cone-bearing version of the pump performed even better, with a success rate of 91%, and it caused fewer side effects than the earlier design. Who this helps: This research benefits patients with advanced heart failure who are awaiting a transplant.

Plain English
This paper examines the progress in left ventricular assist devices (LVADs), which help treat patients with severe heart failure. Over the past 50 years, improvements in these devices have made them smaller, longer-lasting, and less prone to infections, leading to better outcomes for patients (for example, modern pumps are significantly more durable than older models). This research is important because it highlights how continued advancements can enhance the use of LVADs, potentially leading to earlier and more effective treatments for heart failure patients. Who this helps: Heart failure patients.

Plain English
This study looked at a strategy to help a patient who couldn't have blood transfusions due to their beliefs while they were being supported by a heart device called the Impella 5.5. The treatment helped maintain the patient's blood levels over 19 days, and their platelet count improved, with no serious complications. This approach is important because it can help patients like Jehovah's Witnesses and those waiting for heart transplants avoid potential issues linked to blood transfusions. Who this helps: Patients who refuse blood transfusions and those in need of heart transplants.

Plain English
This study focused on improving the blades of a small heart pump designed for infants, known as the NeoVAD. Researchers used advanced computer modeling techniques to test and optimize the blades, resulting in a 5.51% increase in pump efficiency, which is a significant 20.9% improvement compared to the best current design. These findings are important because a more efficient pump can lead to better support for young patients with heart issues. Who this helps: This helps infants with heart problems and their doctors.

Plain English
This study looked at a new testing method for rotary blood pumps, specifically focusing on how to reduce damage to blood when it comes into contact with pump parts. Researchers found that changing the design of a motor bearing by adding a pipe to improve blood flow reduced harmful blood conditions by minimizing trauma. This is important because it allows for better evaluation of blood damage caused by pump components, which is crucial for designing safer heart devices for children. Who this helps: Patients, especially children needing heart assistance devices.

Plain English
This study looked at special receptors called ectopic olfactory receptors (ORs) in the human heart to understand their role in heart failure, specifically in patients with heart damage from blood flow issues. Researchers analyzed heart tissue from 18 patients with heart failure and 4 healthy individuals, finding over 160 different ORs present in the heart, with 38 of these receptors changing when heart failure occurred. These findings are important because they suggest that the altered functioning of these receptors could help explain heart failure’s effects on energy use and inflammation, potentially leading to new treatments. Who this helps: This helps patients with heart failure and doctors looking for better treatment options.

Plain English
This study looked at how well continuous-flow ventricular assist devices (CF-VADs) help adult patients with congenital heart disease who are experiencing severe heart failure. Out of 18 patients, most received durable CF-VADs, with 93% surviving to leave the hospital, and they had an average support time of nearly 26 months. The research highlights that these devices can be effective temporary and long-term solutions for patients with complex heart conditions, making a significant impact on their quality of life and survival rates. Who this helps: This benefits adult congenital heart disease patients and their healthcare providers.

Plain English
This study focused on testing a new system designed to evaluate the compatibility of materials used in a heart pump for children called a left ventricular assist device (LVAD). The researchers developed a magnetic levitated bearing system that can spin at speeds of up to 1,200 rotations per minute without causing damage to blood cells. Their findings are important because they help improve how we assess whether components of these heart pumps are safe for patients, ultimately leading to better outcomes for individuals with heart issues. Who this helps: This helps patients with heart conditions, especially children needing heart pumps.

Plain English
This study focused on improving devices that help children with severe heart problems called left ventricular assist devices (LVADs). Researchers created a system to test how different parts of these devices interact with blood, which can be important for avoiding damage to red blood cells. They found that their new magnetic control method could effectively stabilize the device, with an average prediction error of only 8.8% in one design, helping to ensure safety and effectiveness in future devices. Who this helps: This benefits children with heart conditions who need LVADs, as well as the doctors treating them.

Plain English
This study focused on creating a 3D-printed model of the human heart and blood vessels that can imitate how blood flows in the body. Researchers designed this model to replicate essential heart functions, allowing for precise control of blood flow. This matters because it provides a realistic training tool for surgeons, helping them practice procedures in conditions that closely resemble those found in actual patients. Who this helps: This benefits surgeons and medical professionals.

Plain English
This study looked at how patients who were on dialysis before receiving a heart device called a continuous-flow left ventricular assist device (CF-LVAD) fared after the procedure. Out of 621 patients, 31 had been on dialysis, with 17 on long-term dialysis and 14 on short-term dialysis. The findings showed that those on long-term dialysis had significantly better chances of survival six months (64.7% vs. 14.3%) and one year (58.8% vs. 7.1%) after the surgery compared to those on short-term dialysis, indicating that stable long-term dialysis patients can do well after the heart device is implanted. Who this helps: This benefits patients with chronic kidney disease who are stable on long-term dialysis and need heart support.

Plain English
Researchers replaced the hearts of eight calves with mechanical pumps that provide continuous, smooth blood flow (rather than the natural heartbeat's pulsing action) and kept the animals alive for an average of nearly 60 days. Blood tests, organ function markers, and tissue examinations showed that the calves' organs remained healthy throughout this period, and several calves could even exercise on a treadmill. This proves that a completely artificial heart using this continuous-flow technology can work long-term without damaging the body's organs, opening the door to developing this technology for humans who need heart transplants.

Plain English
This study focused on creating a new testing system to improve heart pumps for children who have heart failure. The researchers looked at how different sizes of motor parts affect both the pump's performance and the potential damage to blood, aiming for an ideal size that minimizes blood trauma while still providing enough power. They found that to keep blood damage low, the motor design should limit shear stress to 30 Pascals, which is a measure of how much strain the blood experiences. Who this helps: This benefits pediatric patients with heart failure and their doctors by improving the safety and effectiveness of heart pumps designed for kids.

Plain English
This study looked at how well a special device that helps the heart pump, called a continuous-flow left ventricular assist device (CF-LVAD), works in adults who have had surgery for certain heart problems called transpositions of the great vessels. The researchers followed three patients and found that it is possible to successfully implant this device in individuals who had previous heart surgeries related to their congenital heart disease. This is important because it offers a potential treatment option for adults with complex heart conditions who are facing severe heart failure. Who this helps: This helps patients with congenital heart disease who develop severe heart failure as adults.

Plain English
Researchers documented a 25-year-old man who wore an artificial heart pump for over 5 years—longer than any previously reported case—and then successfully had it removed when his own heart recovered enough to work on its own. Artificial heart pumps save lives in people with severe heart failure, but they carry serious risks like stroke and infection, so doctors ideally want to remove them once the heart heals. This case shows that even after many years of pump support, a patient's heart can still recover enough to function without it, and doctors should keep trying to wean patients off these devices rather than assuming they'll need them forever.

Plain English
This study looked at two patients who developed a serious condition called heparin-induced thrombocytopenia, which can occur when using a common blood thinner during heart surgery. The researchers found that using a treatment called plasmapheresis, which removes harmful antibodies from the blood, effectively improved their condition before they had surgery to implant a heart pump. This is important because it shows that plasmapheresis can help patients with this specific problem get the treatment they need safely. Who this helps: This helps patients with heparin-induced thrombocytopenia who require heart surgery.

Plain English
This study focused on how well different types of total artificial hearts can balance blood flow between the lungs and the rest of the body without needing active adjustment. Researchers tested four types of rotary blood pumps (RBPs) and found that none of them completely met the desired flow balancing standards, but the VentrAssist and HeartAssist 5 pumps performed the best. Improving the balance could lead to fewer manual adjustments needed, which makes these artificial hearts safer and easier to use. Who this helps: This benefits heart failure patients who may need a total artificial heart.

Plain English
This study examined whether Factor Xa inhibitors like apixaban or rivaroxaban are effective and safe for patients with continuous-flow left ventricular assist devices (CF-LVAD) who were not doing well on warfarin, the usual blood thinner. The researchers looked at seven patients over a decade and found that while those on warfarin had complications such as strokes and serious bleeding, the patients who switched to Factor Xa inhibitors had fewer issues—none experienced strokes or pump thrombosis. This is important because it offers a potentially safer alternative for patients struggling with warfarin, improving their overall treatment options. Who this helps: Patients with CF-LVAD who have had problems with warfarin.

Plain English
This study looked at improving the design of a blood pump used in heart failure treatments, specifically focusing on its motor system to minimize damage to blood during its use. Researchers tested a new motor design that reduces blood exposure time and trauma while maintaining enough power to run the pump effectively. They found that by optimizing the distance between the motor parts, known as the air-gap, they could enhance the pump's performance and safety for patients. Who this helps: This benefits patients with heart failure who rely on these mechanical pumps for treatment.

Plain English
This study looked at the long-term outcomes of a heart surgery called heterotopic cardiac transplantation, where a new heart is added while the patient's original heart remains in place. Out of 39 patients studied, the survival rates were 69% after one year, 36% after five years, and 21% after ten years, with one patient living for 25 years post-surgery. The surgery is especially beneficial for obese patients and those with high pulmonary vascular resistance, as their original heart function often stabilizes over time. Who this helps: This helps patients with severe heart issues, particularly those who are obese or have high blood pressure in their lungs.

Plain English
This study looked at the long-term survival of a 46-year-old man who used a HeartMate II device to help his heart pump blood after multiple heart surgeries. After 10 years, he is still alive and has been able to work without issues while taking medication to prevent blood clots. The success might be due to good placement of the device and effective surgical techniques, indicating that careful procedures may lead to better outcomes for patients with similar heart conditions. Who this helps: This helps patients with advanced heart problems and their doctors by showing the potential long-term success of heart assist devices.

Plain English
This study looked at 25 patients who needed to have their heart-assisting devices replaced more than once due to issues like device failures or complications. They found that 68% of patients were able to leave the hospital after their repeated procedures, with a 1-year survival rate of 72% and a 2-year survival rate of 60%. This is important because it shows that replacing these devices is a viable option for patients with ongoing complications, which could improve their quality of life and chances of recovery. Who this helps: Patients with heart failure who rely on LVADs for support.

Plain English
In this study, researchers looked at the effectiveness of different risk assessment scores in predicting survival rates for patients who received a heart assist device (CF-LVAD). They analyzed data from 605 patients and found that the average Post Cardiac Surgery (POCAS) score accurately predicted 30-day and 90-day survival with an accuracy rate of around 87% and 82%, respectively. For predicting one-year survival, the average Right Ventricular Failure Risk Score (RVFRS) was most effective, achieving an accuracy rate of about 79%. These findings are important as they can help doctors better assess which patients are at higher risk of complications after surgery and guide their future care plans. Who this helps: This helps doctors and healthcare providers working with heart failure patients.

Plain English
Researchers studied a new way to design small heart pumps, known as miniature left ventricular assist devices (LVADs), which help people with heart failure. They created a statistical model that predicts how well these pumps will perform based on different design variables, instead of relying on time-consuming experiments. Their findings showed that this model accurately predicted the performance of two test pumps, which can speed up the design process. Who this helps: This helps heart failure patients who could benefit from better, faster-designed heart pumps.

Plain English
This study looked at how well elderly patients, specifically those over 60, did after receiving the HeartMate II left ventricular assist device (LVAD) to help their hearts. Out of 107 older patients, about 69% survived six months after the device was implanted, but they also faced several complications, such as gastrointestinal bleeding in 34% and infections in nearly 22%. The findings show that older patients can gain significant benefits from this heart support device, suggesting that age should not limit their access to this treatment. Who this helps: Older patients with heart problems who may need mechanical support.

Plain English
This study looked at two main treatments for patients with advanced heart failure: ventricular assist devices (which help the heart pump blood) and heart transplants. Researchers found that while heart transplants provide the best survival rates and improved quality of life, only about 2,500 patients receive them each year due to a shortage of donor hearts. In contrast, the use of ventricular assist devices has increased significantly, now surpassing heart transplants, especially for patients who can't get transplants. Who this helps: This benefits patients with advanced heart failure and their doctors by providing more treatment options.

Plain English
This study describes the unique case of a man who received a heterotopic heart transplant, where one heart is placed alongside the patient's own failing heart, and lived with it for 25 years. Despite significant mismatches in genetic compatibility, the transplanted heart functioned well until complications arose, leading to additional interventions like a total artificial heart and eventually a traditional heart transplant. This case shows that even with challenges, innovative treatments can lead to long-term survival in patients with severe heart conditions. Who this helps: This benefits patients with severe heart failure and their doctors by providing insights into long-term transplant success and management strategies.

Plain English
This study looked at whether performing surgery to fix or replace the tricuspid valve at the same time as implanting a left ventricular assist device (LVAD) helps patients with severe tricuspid valve issues. Researchers reviewed records from 526 patients and found that while overall survival rates and other major health outcomes were similar, patients who had the tricuspid valve surgery had significantly fewer hospital readmissions within 30 days (about 11% compared to those without surgery). This matters because it indicates that while the surgery doesn’t improve overall survival or major complications, it helps reduce immediate hospital visits after the procedure. Who this helps: This helps patients undergoing LVAD implantation and their doctors.

Plain English
The study looked at infections related to a specific heart pump, the Jarvik 2000, when the device’s power line exited the body from the lower rib area, known as a subcostal site. Out of 81 patients over nearly 14 years, there were only five minor infections linked to the pump, resulting in a very low infection rate of 0.002 infections per patient-year. This is important because it shows that using a subcostal exit site can effectively minimize infection risks, similar to previous findings with another exit site. Who this helps: This information benefits patients receiving heart pumps and the doctors who treat them.

Plain English
This study looked at the deaths caused by brain problems in patients using a type of heart support device called a continuous-flow left ventricular assist device (CF-LVAD). Out of 526 patients treated with this device, 141 (about 27%) experienced brain issues, and 48 of those (about 9%) died from them. The study found that being older and having certain health conditions raised the risk of death from these brain problems, which highlights the need for better prevention strategies for patients using CF-LVADs. Who this helps: This information benefits doctors and patients using CF-LVADs.

Plain English
This study looked at patients with severe heart failure who received a continuous-flow left ventricular assist device (CF-LVAD) and whether having a valve repair or replacement at the same time affected their survival. Out of 526 patients, 91 had a valve procedure alongside the CF-LVAD implantation. The survival rates for those with just the CF-LVAD were similar to those who also had a valve repair, indicating that adding a valve procedure doesn't increase the risk of death in the short or mid-term. Who this helps: This information helps doctors decide on the best treatment approach for patients with heart failure and valve issues.

Plain English
This research studied the creation of a bioartificial heart using decellularized pig hearts as scaffolds. The scientists found that when these hearts were implanted in living animals, they encouraged the growth of important heart cells, with signs of new heart tissue forming after long-term implantation. This work is crucial because it shows that it might be possible to create functional heart tissue using the body’s own repair mechanisms, moving us closer to developing a complete artificial heart. Who this helps: This helps patients with heart disease who may need transplants.

Plain English
This study looked at how two types of heart pumps, the EXCOR and HeartMate II (HMII), interact with blood in children, aiming to improve future devices for young patients. The researchers found that both devices caused an increase in harmful substances in the blood over time, with HMII causing a greater increase in harmful hemoglobin levels—0.085 grams for HMII compared to 0.003 grams for EXCOR. Understanding these effects is important to develop safer and more effective heart devices for children, as currently only one pediatric-specific device is approved in the U.S. Who this helps: This research benefits children needing heart support, as well as doctors who treat them.

Plain English
This study looked at the use of total artificial hearts (TAHs) to help patients waiting for heart transplants. It found that patients with TAHs have a high success rate of 85% in getting a transplant and surviving after the procedure, which is comparable to those using other types of heart support devices. Improvements in TAH technology, like smaller sizes and better materials, are expected to make these devices even more effective in helping patients with severe heart issues. Who this helps: This helps patients with advanced heart failure who are waiting for a transplant.

Plain English
Researchers studied a new intra-atrial pump (IAP) designed to help the left side of the heart work better in patients with early-stage heart failure. They tested two different designs for the pump blades and found that one design (with a steep pressure/flow curve) worked better than the other when the pump was inserted into the left atrium. This approach created a healthier blood flow environment, although it was not as effective as traditional methods that connect to the left ventricle. Who this helps: This benefits patients with early-stage heart failure.

Plain English
This study looked at a new device called an intra-atrial pump (IAP) designed to help people with early-stage heart failure by assisting their weak left ventricle. The researchers used a cow model to test the pump and found that it could safely create blood flow support of 1 to 3 liters per minute without harming surrounding heart tissue. This is important because it shows the pump can effectively improve blood circulation in living organisms, which may lead to better treatment options for heart failure patients. Who this helps: Patients with early-stage heart failure.